OBJECTIVES: To evaluate the cost-effectiveness of brentuximab vedotin in patients with relapsed/refractory Hodgkin Lymphoma as compared to Chemotherapy/Chemotherapy with stem cell transplantation as first line therapy from a US healthcare perspective. METHODS:  An Excel based Markov model was developed with three health states to follow the clinical end points reported in the AETHERA clinical trial. Health states included were Progression free survival, Progressed disease and Death. Progressed disease was defined as disease that progressed with time in scope and/or severity. Brentuximab vedotin was compared with the first line treatments like chemotherapy or chemotherapy with stem cell transplantation. The model outcomes were quality-adjusted life years (QALYs) and incremental cost per QALY. Model inputs such as transition probabilities, cost of drug and procedures, resource utilization and utilities of each health states were used from previously published literature. Due to short follow-up of patients in the trial, an extrapolation was assumed by holding fixed the relative rates observed in the trial to observed overall survival and progression free survival for a life time horizon. Deterministic and probabilistic sensitivity analysis was performed in the end to assess the effect of uncertainties in the model.